Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone
收藏DataCite Commons2025-10-07 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011839/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).
提供机构：
Vivli
创建时间：
2025-10-06
